Attorneys for Novo Nordisk and patients alleging the makers of Ozempic and similar drugs didn’t adequately warn users of side effects met Thursday for their first case management conference at a federal court in Pennsylvania.
Eighteen cases have already been consolidated in the US District Court for the Eastern District of Pennsylvania, and at least 37 other pending lawsuits await consolidation orders, according to the transfer order filed February. Judge Gene E.K. Pratter is overseeing the multidistrict litigation.
Most of the cases are related to prescribed use and will center on a condition called gastroparesis, which affects stomach contractions and ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.